On Korea: Academic Paper Series
From the Issue
On Korea: Academic Paper Series 2022About On Korea: Academic Paper Series
In December 2006, KEI initiated our Academic Paper Series in which we commission up to 10 papers per year with diverse perspectives on original subjects of current interest to Korea watchers. This year-long program provides both leading Korea scholars and new voices from around the world to speak and write on trends and events affecting the Korean peninsula.
South Korea aspires to achieve the status of a global vaccine hub as a national strategic policy priority. South Korea’s biomanufacturing industry has ramped up the development and production of therapeutic treatments and vaccines to meet the public health demands of the pandemic. The government has responded by promoting public-private partnerships to expand vaccine production capacity to meet current and future needs domestically and abroad in LMICs. To bolster this strategy, the government has entered into partnerships with international organizations, namely the WHO, ADB, and IVI, by establishing training hub programs for a global biomanufacturing workforce in 2022. This paper examines South Korea’s mechanisms and strategy towards becoming a vaccine hub, the origins of which predate the Covid-19 pandemic but were again spurred by vaccine nationalism and challenges to access early in the pandemic.